Advances In The Biology And Management Of Plasma Cell Dyscrasias

This unique book focuses on the non-myeloma plasma cell dyscrasias. A key resource for this group of diseases, the book features the latest in emerging knowledge and therapeutic developments, including novel therapies. Each disease-specific chapter discusses biology, disease course, and appropriate therapeutic interventions, covering plasma cell leukemia, plasmacytoma, POEMS Syndrome and Castleman's Disease, Waldenström macroglobulinemia, immunoglobin deposition disease, and cryoglobulinemic syndromes, among others. The only book dedicated to this intriguing family of diseases, Biology and Management of Unusual Plasma Cell Dyscrasias will be a long-lasting reference for clinicians and scientists alike.

This book provides a concise overview of the state of the art in the biology and treatment of plasma cell malignancies, a heterogeneous group of diseases primarily characterized by the presence of clonal plasma cells within the bone marrow or extramedullary sites. The plasma cell dyscrasias investigated include monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, plasmacytoma, immunoglobulin deposition diseases (primary amyloidosis and systemic light and heavy chain deposition diseases), and Waldenström’s macroglobulinemia. In the case of multiple myeloma, the coverage ranges from genomic aberrations and microRNAs to treatment for different patient groups, upcoming novel therapies, immunotherapy, and transplantation. The book reflects the significant research advances achieved in this field during the past few years, which have enhanced our understanding of the molecular mechanisms responsible for the pathogenesis of plasma cell dyscrasias.

Expert physicians and clinical researchers summarize and explain all the recent advances in the biology and treatment of bone marrow-based malignancy. On the biological side, the authors show the characteristics of the malignant cell and describe the significant roles played by oncogenic changes, chromosomal anomalies, Kaposi's sarcoma herpes virus, and cytokines. New epidemiological findings and prognostic factors are also analyzed. On the clinical side, the authors provide a comprehensive review of conventional treatment regimens, as well as a discussion of newer experimental approaches involving immunologic targeting, inhibitors of drug resistance, and antitumor agents.

Preceded by: Clinical clerkship in inpatient medicine / Sanjay Saint. 3rd ed. c2010.

This book was prompted by a renewed interest in the biology of myeloma, new concepts with regard to its clinical evolution, and options for therapy that have not been available before. Myeloma has always involved many systems and caused many problems for the clinician. It has become a focus of attention for the scientist and clinician.

This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care. Our understanding of this group of disorders is developing at an unprecedented rate, and Multiple Myeloma meets the need among oncologists and hematologists for a clear, timely, and authoritative resource on their biology, diagnosis, and treatment.

The Chemotherapy Source Book, Fourth Edition pulls together all the current information on the chemotherapeutic management of cancer patients, including choice of chemotherapeutic agents, use of combinations, and toxicity of individual drugs. Organized by disease site, the book brings together pharmacologic and patient management information in one source that clinicians can consult for any question encountered in the delivery of chemotherapy. This updated Fourth Edition includes new drugs as well as new indications for older drugs. Content has been streamlined to provide essential information more quickly for the busy practitioner. Plus, this edition is softcover for greater portability and convenience.